Company: SCLXW
Filing Date: 2025-12-29
Form Type: 424B3
Source: 0001193125-25-335429
Chunk: 527

Company: Scilex Holding Co
Filing Date: 2025-12-29
Form: 424B3
Chunk 527
---
 Purchase Agreement. The $50.0 million of total proceeds received were allocated based on their relative fair value to the Tranche B Notes, the October 2024 Noteholder Warrants, and the ZTlido Royalty Purchase Agreement, with the excess of fair value over the proceeds received in amount of $2.6 million recognized as a loss upon issuance in change in fair value of debt and liability instruments in the consolidated statement of operations during the year ended December 31, 2024. F-33

The following table provides a summary of the changes in the balance and the estimated fair value of the Tranche B Notes (in thousands):

| Beginning Balance as of October 8, 2024 |     | December 31, 
 2024         | 42,740 |   |
|:----------------------------------------|:----|:-------------|-------:|:--|
| Conversion of Tranche B notes           |     |              | (9,255 | ) |
| Repayment of Tranche B Notes            |     |              | (3,283 | ) |
| Change in fair value of Tranche B Notes |     |              | (6,641 | ) |
| Ending Balance as of December 31, 2024  |     | $            | 23,560 |   |

Aggregate principal repayments for the Company’s outstanding debt will be $47.7 million and $19.5 million in 2025 and 2026, respectively. ZTlido Royalty Purchase Agreement On October 8, 2024, in connection with the closing of the transactions contemplated by the Tranche B Securities Purchase Agreement, the Company and Scilex Pharma entered into the ZTlido Royalty Purchase Agreement with the ZTlido Royalty Purchasers. Pursuant to the ZTlido Royalty Purchase Agreement, Scilex Pharma sold to the ZTlido Royalty Purchasers the right to receive 8% of all aggregate net sales worldwide (the “ZTlido Purchased Receivables”) with respect to ZTlido, SP-103and any related, improved, successor, replacement or varying dosage forms of the foregoing, which shall be paid within 60 calendar days after the end of each calendar quarter. In full consideration for the sale, transfer, conveyance and granting of the ZTlido Purchased Receivables, and subject to the terms and conditions set forth in the ZTlido Royalty Purchase Agreement,